IDRA News and Press, Idera Pharmaceuticals Inc. From 12/14/21

Updating the progress of clinical trials for the company’s Toll-like receptor 9 agonist, tilsotolimod, Idera Pharmaceuticals (NASDAQ:IDRA) said that its partner AbbVie (NYSE:ABBV) has discontinued further patient enrollment in an early-stage study for a combination therapy involving th...

EXTON, Pa., Dec. 14, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” and “our”) (Nasdaq: IDRA) today announced clinical updates regarding tilsotolimod, its synthetic Toll-like rec...

Penny Stocks To Buy According To 4 Analysts Right Now If you’re looking for penny stocks to buy, you might be looking for specific trends. We’ve covered many of these over the last few weeks. Whether it’s stocks with low floats, penny stocks with high short inte...

Idera Pharmaceuticals (NASDAQ:IDRA): Q3 GAAP EPS of -$0.11. Press Release Cash position as of September 30, 2021 was $36.6 million. For further details see: Idera Pharmaceuticals reports Q3 results

EXTON, Pa., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera,” the “Company,” “we,” “us,” or “our”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended Sept...

EXTON, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the second quarter ended June 30, 2021. “Our goal is to add new development o...

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

Foryou13/iStock via Getty Images Shares of Idera Pharmaceuticals (IDRA) are up 22% in morning trading. An SEC filing after the closing bell yesterday showed that Chief Operating Officer Daniel Soland bought 50K shares at $1.19/share on June 18. The executive now owns 78,843 shares. Earlier th...

Gainers: Idera Pharmaceuticals (IDRA) +22%, Beyond Air (XAIR) +14%, Clover Health Investments (CLOV) +14%, Adial Pharmaceuticals (ADIL) +13%, CollPlant Biotechnologies (CLGN) +10%.Losers: Mereo BioPharma (MREO) -9%, Portage Biotech (PRTG) -9%, ...

vTv Therapeutics (VTVT) +28% on licensing agreement with Cantex.Adial Pharmaceuticals (ADIL) +22%.Bio-Path Holdings (BPTH) +22% as USPTO grants a new patent.Beyond Air (XAIR) +12%.Sanderson Farms (SAFM) +12% as it explores a potential sale.Idera Pharmaceuticals (IDRA) +11%.Insp...